← Back

SYoung Group Co Ltd

SYoung Group Co., Ltd. engages in the research and development, production, and sale of cosmetic products in China. It provides facial masks, lotions, creams, makeup, and cleansing and personal care products. The company sells its products under the Yunifang, EVIDENSDEBEAUT, PIERAUG, RVive, Yu Nifang, Big Water Drop, Little Mihu, VAA and other brands. It offers its products a through e-commerce platforms, such as Tmall, Taobao, Douyin, JD.com, Vipshop, Pinduoduo, Kuaishou, and other mainstream e-commerce platforms; offline channels, including brand-owned stores; department stores, such as SKP, Sephora, and Intime Department Stores; and supermarkets, such as Walmart and Yonghui; and beauty stores comprising Watsons, KKV, and Colorist. The company was formerly known as Yujiahui Co., Ltd. and changed its name to SYoung Group Co., Ltd. in March 2021. SYoung Group Co., Ltd. was founded in 2006 and is headquartered in Changsha, China.

Price · split & dividend adjusted
News & notes moving 300740.CS
300740.CS

Beauty and personal care sector surges over 3.5% intraday, cosmetics retail sales hit a near-decade high for the same period

The beauty and personal care sector rose 3.58% intraday. Lafang China gained 9.98%, SYoung Group rose 6.35%, Marubi Biotechnology climbed 5.03%, Shanghai Jahwa advanced 4.31%, and Huaye Spice added 4.12%. According to the National Bureau of Statistics, cosmetics retail sales in June 2026 reached 45.6 billion yuan, the highest for the same month in nearly a decade, up 12.6% year-on-year. For the first six months, total cosmetics retail sales amounted to 244.5 billion yuan, a year-on-year increase of 6.3%. Haitong International noted that China's cosmetics industry entered a stock competition phase in 2026, with full-year retail sales growth expected to reach 11%, and the market share of domestic brands likely to rise to 51%. Shenwan Hongyuan believes the industry is entering a new development cycle driven by efficacy innovation, where research and development of functional ingredients and clinical validation capabilities will become core competitive barriers.
21世纪经济·31dRead more ▾